BioThrust

BioThrust sells ComfyCell Incu bioreactor systems, control units, and single-use vessels for sensitive cell cultivation.

BioThrust’s application studies demonstrate how bionic bioreactors improve stem cell-based biomanufacturing.

BioThrust’s research paper introduces the Membrane Stirrer concept, which underpins the ComfyCell bioreactor technology.

Scalable hiPSC and iPSC-derived NK-cell expansion in a low-shear, bubble-free bioreactor. BioThrust’s ComfyCell platform achieved more than 1 billion viable hiPSCs in seven days and 4.6 billion viable iPSC-derived progenitor NK cells after direct scale-up to 2 L.

The BioThrust ComfyCell is a highly capable system to scale up iPSC-derived organoids, e.g. to generate in-vivo-like lung tissue.

The company’s membrane-stirred bioreactor produces matrix-free human lung organoids at a 2-liter scale while preserving lung-like cellular diversity.

BioThrust offers career opportunities in scalable stem cell cultivation.

Our affordable, easy to use yet scalable incubator-based bioreactor, the perfect for early CGT process development.

BioThrust can upgrade existing bioreactor glass vessels with its Membrane Stirrer technology.

BioThrust offers the first scalable and controllable cell therapy manufacturing solution.

BioThrust’s team of biologists, engineers, and scientists developed a scalable solution for stem cell cultivation.

BioThrust provides the first scalable and controllable cell therapy manufacturing solution.

BioThrust’s bionic bioreactors enable scalable and controllable cell and gene therapy (CGT) manufacturing through high gas transfer, low shear force, and foam-free operation.

BioThrust GmbH, Pauwelsstraße 17, 52074 Aachen, Germany

BioThrust develops a lung-mimicking bioreactor to cultivate fragile stem and immune cells for therapies. The device addresses limitations of conventional stirred tanks and wave bags, which damage cells under shear forces and restrict production to small volumes. By improving scalability, BioThrust aims to reduce costs in cell therapy manufacturing, a key barrier to wider adoption.

Oct 2026eiceuNews article

BioThrust secures additional pre-seed funding to advance its **ComfyCell** bioreactor platform, designed to improve efficiency and scalability in stem cell production for cell and gene therapies. The technology targets streamlined manufacturing processes in biotech applications. The company focuses on overcoming key barriers in therapeutic development through hardware innovation.

Apr 2026startup.euNews article

KISSEN introduces a bubble-free membrane stirrer to improve oxygen supply in stem cell bioreactors, addressing scalability limits in conventional systems. The innovation preserves sensitive cell cultures while enabling larger production volumes, lowering costs for stem cell therapies. This advancement supports broader adoption of cell-based treatments by enhancing manufacturing efficiency.

Nov 2025Federal Ministry of Education and Research - BMBF GO-BioNews article

BioThrust, a spin-off from RWTH Aachen, receives a seven-figure investment from Freigeist Capital. The funding supports the biotech company’s development and growth. BioThrust focuses on advancing biotechnology solutions through its research and innovation pipeline.

Jan 2024startuprise.co.ukNews article